Details for New Drug Application (NDA): 083101
✉ Email this page to a colleague
NDA 083101 describes PROPOXYPHENE COMPOUND-65, which is a drug marketed by Sandoz and is included in one NDA. Additional details are available on the PROPOXYPHENE COMPOUND-65 profile page.
The generic ingredient in PROPOXYPHENE COMPOUND-65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
The generic ingredient in PROPOXYPHENE COMPOUND-65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
Summary for 083101
| Tradename: | PROPOXYPHENE COMPOUND-65 |
| Applicant: | Sandoz |
| Ingredient: | aspirin; caffeine; propoxyphene hydrochloride |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 389MG;32.4MG;65MG | ||||
| Approval Date: | Jun 24, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
